23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Insights

The financial performance of 23andMe for Q4 and FY2024 paints a somewhat challenging picture for the company. Total revenue for Q4 was $64 million, a significant decline of 31% compared to the prior year's quarter. The primary driver for this drop was the end of the GSK collaboration, which likely had a considerable impact on their research revenue. Additionally, lower sales of PGS kits and telehealth orders further contributed to this decline. The full year revenue also saw a substantial decrease from $299 million in FY2023 to $220 million in FY2024, representing a 27% decrease.

On the cost front, operating expenses surged to $239 million in Q4, largely due to a $153 million non-cash goodwill impairment charge. This indicates a significant write-down in the value of the company's acquisitions, pointing to possible overvaluation at the time of purchase. Net loss for Q4 was reported at $209 million, compared to $64 million in the previous year, underlining the financial strain the company is under.

One positive note is the reduction in Adjusted EBITDA loss from $39 million in Q4 FY2023 to $33 million in Q4 FY2024, primarily due to cost-cutting measures. Cash and cash equivalents also decreased significantly to $216 million from $387 million a year ago, which may raise concerns among investors about the company's liquidity and potential need for additional financing.

Overall, the financial outlook for 23andMe appears to be challenging, with key revenue streams declining and significant impairment charges reflecting potential overvaluation of past acquisitions.

The formation of a Special Committee to review strategic alternatives and the potential bid by CEO Anne Wojcicki to acquire all outstanding shares she does not currently own are noteworthy developments. Such moves could imply that the internal management perceives the current stock price undervalues the company. However, this can also be a sign of a strategic shift or a need to stabilize the company's direction amid financial challenges. The fact that strategic alternatives are being considered suggests a recognition of potential structural issues or the need for a significant change in strategy to unlock shareholder value.

The market often reacts positively to insider bids as they are seen as a vote of confidence from the management. However, investors should be cautious and consider the broader financial health of the company and the reasons behind such a move. It’s also important to monitor the outcomes of these strategic alternatives reviews closely, as they will shape the future trajectory of 23andMe.

The company's strides in advancing its clinical programs are notable. The dosing of the first patient for the Phase 1 clinical trial of 23ME-01473, targeting cancer, is a positive indication of progress in their therapeutics pipeline. The dual-mechanism NK cell activator could potentially be a game-changer in cancer treatment if it shows positive results. The upcoming presentations at ASCO for 23ME-00610 also highlight ongoing research and progress in their clinical trials.

However, these developments are still in the early stages and the outcomes are uncertain. Clinical trials are lengthy and costly and there is no guarantee of success or regulatory approval. Investors should be aware of these risks and the potential for future positive announcements from ongoing studies. It's essential to track the progress and clinical results over time to gauge the real value these programs could bring to 23andMe.

05/23/2024 - 04:05 PM

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024.

Key Results and Recent Developments

On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review strategic alternatives that may be available to 23andMe to maximize shareholder value. On April 18, 2024 the Company announced it has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own.
Reported total revenue of $64.0 million in the fourth quarter of fiscal 2024, compared to $92.4 million in the fourth quarter of fiscal 2023, a decrease of approximately 31% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes and telehealth orders. Full year 2024 revenues were $219.6 million compared to $299.5 million for full year 2023.
Launched new 23andMe+ Premium ancestry feature called Historical Matches, connecting customers to one or more of 335 historical individuals, weaving ancestral connections into the story of human history and migration.
Announced availability of three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database. These PRS reports calculate the potential likelihood of an individual developing one of these cancers, based on thousands of genetic variants associated with the disease.
Announced dosing of the first patient for Phase 1 clinical trial for 23ME-01473, a dual-mechanism natural killer (NK) cell activator, targeting ULBP6, intended to treat cancer. The Company expects to continue to enroll patients throughout fiscal year 2025 and announce results of the study later in calendar year 2025.
Presented posters for 23ME-00610 and 23ME-01473 therapeutics programs at the American Association for Cancer Research (AACR) annual meeting and completed enrollment of the 23ME-00610 phase 1/2a clinical trial in April 2024.
Will be presenting posters at ASCO on the neuroendocrine cohort (June 1) and ovarian cohort (June 3) for 23ME-00610, the first data presentations from the Phase 2a expansion cohorts.
On May 9, 2024 the Company received a notification letter from Nasdaq notifying the Company that it had been granted an additional 180 days, or until November 4, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

“The Company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advancing our clinical stage assets,” said Anne Wojcicki, Co-Founder & CEO of 23andMe. “We continue to work to build value for customers and shareholders and are looking forward to a transformative FY2025.”

Q4 Fiscal 2024 Financial Results
Total revenue for FY24 Q4 was $64 million, compared to $92 million for the same period in the prior year, representing a decrease of 31%. The decrease was primarily driven by lower research services revenue as the GSK collaboration exclusive discovery term concluded in July 2023, as well as lower consumer services revenue driven mainly by lower PGS kit sales volume and telehealth orders. These decreases were partially offset by higher revenue from growth in our membership services.

Revenue from consumer services, which includes PGS, telehealth and membership services, represented approximately 99% of total revenue for FY24 Q4. Research services revenue accounted for approximately 1% of total revenue for FY24 Q4.

Operating expenses for FY24 Q4 were $239 million, compared to $109 million for the same period in the prior year. The increase in operating expenses was primarily due to a $153 million non-cash goodwill impairment charge taken in the quarter, reflecting the remaining balance of the consumer and research services segment’s goodwill acquired as part of the acquisition of Lemonaid Health Limited. The increase was partially offset by lower personnel-related expenses following workforce reductions in prior quarters along with the disposition of Lemonaid Health Limited in the UK in August 2023 and lower R&D spend due to a significant reduction in GSK collaboration programs.

Net loss for FY24 Q4 was $209 million, compared to a net loss of $64 million for the same period in the prior year.

Adjusted EBITDA (as defined below) for FY24 Q4 was a loss of $33 million, compared to a loss of $39 million for the same period in the prior year. The decrease in adjusted EBITDA loss was primarily due to lower personnel-related and R&D expenses, partially offset by lower research services gross profit as the GSK collaboration exclusive discovery term concluded in July 2023, as noted above. Please refer to the tables below for a reconciliation of U.S. GAAP to Non-U.S. GAAP financial measures.

Full Year Fiscal 2024 Financial Results
Total revenue for FY24 was $220 million, compared to $299 million for the prior year, representing a decrease of 27%. The decrease was primarily driven by lower consumer services revenue resulting mainly from lower PGS kit sales volume and telehealth orders, as well as lower research services revenue as a result of the conclusion of the GSK collaboration exclusive discovery term concluded in July 2023. These decreases were partially offset by higher revenue from growth in our membership services revenue.

Revenue from consumer services, which includes PGS, telehealth and membership services, represented approximately 92% of total revenue for FY24. Research services revenue accounted for approximately 8% of total revenue for FY24.

Operating expenses for FY24 were $781 million, compared to $459 million for the prior year. The increase in operating expenses was primarily due to $352 million in non-cash goodwill impairment charges taken in the last two quarters, as discussed above. The increase was partially offset by lower personnel-related expenses following workforce reductions in the year along with the disposition of Lemonaid Health Limited in the UK in August 2023 and reductions in marketing advertising spend aimed to boost margin and marketing efficiency.

Net loss for FY24 was $667 million, compared to a net loss of $312 million for the prior year.

Adjusted EBITDA for FY24 was a loss of $176 million, compared to a loss of $161 million for the prior year. The increase in Adjusted EBITDA loss was primarily due to lower Research Services gross profit as the GSK collaboration exclusive discovery term concluded in July 2023, lower consumer services revenue driven mainly by lower PGS kit sales volume and telehealth orders and increasing Therapeutics expenses, partially offset by lower personnel-related expenses and reductions in marketing advertising spend, as noted above. Please refer to the tables below for a reconciliation of U.S. GAAP to Non-U.S. GAAP financial measures.

Please note the full year fiscal 2024 results are preliminary. The Company is still completing its assessment of its impairment review of goodwill and long-lived assets, and its impairment expense is undergoing further evaluation. This could result in an adjustment to the impairment recorded in the Company’s operating expenses and impact on its net loss. Please note that any adjustment would be a non-cash item and reflected in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024.

Balance Sheet
23andMe ended March 31, 2024 with cash and cash equivalents of $216 million, compared to $387 million as of March 31, 2023.

FY2025 Financial Guidance
In light of the Special Committee review of strategic alternatives, the Company is not providing guidance at this time.

Conference Call Webcast Information
23andMe will host a conference call at 4:30 p.m. Eastern Time today, May 23, 2024, to discuss the financial results for Q4 and FY2024 and report on business progress. The webcast can be accessed at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address.

About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, review of strategic alternatives and associated proposed transactions financial position, financial projections, funding for continued operations, cash reserves, projected costs, plans, potential future collaborations, database growth and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "predicts," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.

Use of Non-GAAP Financial Measures
To supplement the 23andMe’s unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (GAAP), this press release also includes references to Adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to: changes in fair value of warrant liabilities, litigation settlements, gains or losses on dispositions of subsidiaries, transaction-related costs, and cyber security incident expenses, net of probable insurance recoveries, if applicable for the periods presented. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Adjusted EBITDA is a key measure used by 23andMe’s management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe’s annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe’s core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe’s business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe’s management and board of directors.

In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe’s presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe’s performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Adjusted EBITDA is our best proxy for cash burn.

Contacts
Investors: Ian Cooney, ianc@23andMe.com ; investors@23andMe.com
Media: press@23andMe.com

23andMe Holding Co.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)

	Three Months Ended March 31,						Twelve Months Ended March 31,
	2024			2023			2024			2023
Revenue:
Service	$	57,719		$	80,778		$	191,816		$	265,840
Product		6,309			11,599			27,822			33,649
Total revenue		64,028			92,377			219,638			299,489
Cost of revenue:
Service		33,965			48,835			108,116			150,595
Product		3,032			3,560			12,145			14,398
Total cost of revenue		36,997			52,395			120,261			164,993
Gross profit		27,031			39,982			99,377			134,496
Operating expenses:
Research and development		46,724			60,719			205,361			222,596
Sales and marketing		16,931			21,779			85,600			119,927
General and administrative		22,296			26,758			129,772			115,984
Restructuring and other charges		—			—			8,368			—
Goodwill impairment		152,944			—			351,744			—
Total operating expenses		238,895			109,256			780,845			458,507
Loss from operations		(211,864	)		(69,274	)		(681,468	)		(324,011	)
Other income (expense):
Interest income, net		3,042			4,369			14,331			9,676
Other income (expense), net		5			174			506			(93	)
Loss before income taxes		(208,817	)		(64,731	)		(666,631	)		(314,428	)
Provision for (benefit from) income taxes		18			(633	)		73			(2,772	)
Net loss		(208,835	)		(64,098	)		(666,704	)		(311,656	)
Other comprehensive income (loss), net of tax		—			(309	)		620			(799	)
Total comprehensive loss	$	(208,835	)	$	(64,407	)	$	(666,084	)	$	(312,455	)
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Basic and diluted	$	(0.43	)	$	(0.14	)	$	(1.40	)	$	(0.69	)
Weighted-average shares used to compute net loss per share:
Basic and diluted		485,951,909			456,254,405			475,982,265			451,504,377

23andMe Holding Co. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)

	March 31, 2024			March 31, 2023
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	216,488		$	386,849
Restricted cash		1,399			1,399
Accounts receivable, net		3,324			1,897
Inventories		12,465			10,247
Deferred cost of revenue		4,792			5,376
Prepaid expenses and other current assets		16,841			19,224
Total current assets		255,309			424,992
Property and equipment, net		28,351			38,608
Operating lease right-of-use assets, net		48,894			56,078
Restricted cash, noncurrent		6,974			6,974
Internal-use software, net		20,516			15,661
Intangible assets, net		33,255			45,520
Goodwill		—			351,744
Other assets		1,868			3,021
Total assets	$	395,167		$	942,598
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	11,571		$	12,924
Accrued expenses and other current liabilities		42,263			66,430
Deferred revenue		64,827			62,521
Operating lease liabilities		8,670			7,541
Total current liabilities		127,331			149,416
Deferred revenue, noncurrent		10,000			—
Operating lease liabilities, noncurrent		67,845			77,763
Other liabilities		1,471			1,480
Total liabilities		206,647			228,659
Stockholders’ equity
Preferred stock - par value $0.0001, 10,000,000 shares authorized as of March 31, 2024 and 2023; zero shares issued and outstanding as of March 31, 2024 and 2023		—			—
Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 323,394,807 and 293,020,474 shares issued and outstanding as of March 31, 2024 and 2023, respectively; Class B shares, 350,000,000 shares authorized, 166,724,586 and 168,179,488 shares issued and outstanding as of March 31, 2024 and 2023, respectively		49			46
Additional paid-in capital		2,361,559			2,220,897
Accumulated other comprehensive income (loss)		—			(620	)
Accumulated deficit		(2,173,088	)		(1,506,384	)
Total stockholders’ equity		188,520			713,939
Total liabilities and stockholders’ equity	$	395,167		$	942,598

23andMe Holding Co.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Twelve Months Ended March 31,
	2024			2023
Cash flows from operating activities:
Net loss	$	(666,704	)	$	(311,656	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		23,227			32,071
Amortization and impairment of internal-use software		6,255			4,427
Stock-based compensation expense		120,209			116,017
Impairment of long-lived assets		—			10,126
Goodwill impairment		351,744			—
Loss on disposition of Lemonaid Health Limited		2,026			—
Other operating activities		(529	)		77
Changes in operating assets and liabilities:
Accounts receivable, net		(1,427	)		1,483
Inventories		(2,218	)		542
Deferred cost of revenue		584			2,325
Prepaid expenses and other current assets		(1,231	)		6,653
Operating lease right-of-use assets		7,185			7,393
Other assets		1,152			(429	)
Accounts payable		(996	)		(24,573	)
Accrued expenses and other current liabilities		(7,104	)		2,671
Deferred revenue		12,307			(418	)
Operating lease liabilities		(8,790	)		(8,934	)
Other liabilities		(9	)		(3,165	)
Net cash used in operating activities		(164,319	)		(165,390	)
Cash flows from investing activities:
Purchases of property and equipment		(1,129	)		(4,048	)
Proceeds from sale of property and equipment		30			5
Capitalized internal-use software costs		(8,527	)		(7,262	)
Net cash used in investing activities		(9,626	)		(11,305	)
Cash flows from financing activities:
Proceeds from exercise of stock options		909			4,203
Proceeds from issuance of common stock under employee stock purchase plan		3,262			6,464
Payments for taxes related to net share settlement of equity awards		(230	)		(197	)
Payments of deferred offering costs		(357	)		(693	)
Net cash provided by financing activities		3,584			9,777
Effect of exchange rates on cash and cash equivalents		—			385
Net (decrease) increase in cash, cash equivalents and restricted cash		(170,361	)		(166,533	)
Cash, cash equivalents and restricted cash — beginning of period		395,222			561,755
Cash, cash equivalents and restricted cash — end of period	$	224,861		$	395,222
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	$	97		$	473
Stock-based compensation capitalized for internal-use software costs	$	3,606		$	3,191
Deferred offering costs during the period included in accounts payable and accrued expenses	$	1		$	45
Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above:
Cash and cash equivalents	$	216,488		$	386,849
Restricted cash, current		1,399			1,399
Restricted cash, noncurrent		6,974			6,974
Total cash, cash equivalents and restricted cash	$	224,861		$	395,222

23andMe Holding Co.
Total Company and Segment Information and Reconciliation of Non-GAAP Financial Measures
(In thousands)
(Unaudited)

The Company’s revenue and Adjusted EBITDA by segment and for the total Company is as follows:

	Three Months Ended March 31,						Twelve Months Ended March 31,
	2024			2023			2024			2023
Segment Revenue: ⁽¹⁾
Consumer and Research Services	$	64,028		$	92,377		$	219,638		$	299,489
Total revenue	$	64,028		$	92,377		$	219,638		$	299,489
Segment Adjusted EBITDA:
Consumer and Research Services Adjusted EBITDA	$	(3,874	)	$	4,989		$	(36,769	)	$	(17,997	)
Therapeutics Adjusted EBITDA		(17,135	)		(29,904	)		(91,025	)		(88,503	)
Unallocated Corporate ⁽²⁾		(12,199	)		(13,744	)		(48,002	)		(54,801	)
Total Adjusted EBITDA	$	(33,208	)	$	(38,659	)	$	(175,796	)	$	(161,301	)
Reconciliation of net loss to Adjusted EBITDA:
Net loss	$	(208,835	)	$	(64,098	)	$	(666,704	)	$	(311,656	)
Adjustments
Interest income, net		(3,042	)		(4,369	)		(14,331	)		(9,676	)
Other (income) expense, net		(5	)		(174	)		(506	)		93
Provision for (benefit from) income taxes		18			(633	)		73			(2,772	)
Depreciation and amortization		4,160			4,727			18,033			20,239
Amortization of acquired intangible assets		1,775			3,639			11,448			16,486
Impairment of acquired intangible assets		—			—			—			9,968
Stock-based compensation expense		19,011			22,249			120,209			116,017
Litigation settlement cost		—			—			98			—
Loss on disposition of Lemonaid Health Limited and transaction-related costs		—			—			2,375			—
Goodwill impairment		152,944			—			351,744			—
Cybersecurity incident expenses, net of probable insurance recoveries		765			—			1,765			—
Total Adjusted EBITDA	$	(33,209	)	$	(38,659	)	$	(175,796	)	$	(161,301	)

(1)		There was no Therapeutics revenue for the three and twelve months ended March 31, 2024 and 2023.
(2)		Certain department expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, Corporate Development, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.

FAQ

What were 23andMe's Q4 FY24 revenue and net loss?

23andMe reported Q4 FY24 revenue of $64 million and a net loss of $209 million.

How much did 23andMe's full-year FY24 revenue decline?

23andMe's full-year FY24 revenue declined by 27% to $220 million.

What caused the increase in 23andMe's operating expenses for Q4 FY24?

The increase in operating expenses for Q4 FY24 was mainly due to a $153 million goodwill impairment charge.

What new features and reports did 23andMe launch recently?

23andMe launched the 23andMe+ Premium ancestry feature and new genetic reports on breast, colorectal, and prostate cancer.

What clinical trials is 23andMe currently advancing?

23andMe is advancing trials for 23ME-01473 and 23ME-00610, with ongoing enrollment and upcoming data presentations.

What is the status of 23andMe's Nasdaq listing compliance?

23andMe received an extension until November 4, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Why did 23andMe's research revenue decrease in FY24?

Research revenue decreased due to the conclusion of the GSK collaboration exclusivity term in July 2023.

What are 23andMe's plans for FY2025?

23andMe is not providing financial guidance for FY2025 due to the Special Committee's review of strategic alternatives.

23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Insights

FAQ

What were 23andMe's Q4 FY24 revenue and net loss?

How much did 23andMe's full-year FY24 revenue decline?

What caused the increase in 23andMe's operating expenses for Q4 FY24?

What new features and reports did 23andMe launch recently?

What clinical trials is 23andMe currently advancing?

What is the status of 23andMe's Nasdaq listing compliance?

Why did 23andMe's research revenue decrease in FY24?

What are 23andMe's plans for FY2025?

NASDAQ:ME

ME Rankings

ME Latest News

ME Stock Data

Trending News

23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Insights

Financial Analyst negative

Market Research Analyst neutral

Medical Research Analyst positive

FAQ

What were 23andMe's Q4 FY24 revenue and net loss?

How much did 23andMe's full-year FY24 revenue decline?

What caused the increase in 23andMe's operating expenses for Q4 FY24?

What new features and reports did 23andMe launch recently?

What clinical trials is 23andMe currently advancing?

What is the status of 23andMe's Nasdaq listing compliance?

Why did 23andMe's research revenue decrease in FY24?

What are 23andMe's plans for FY2025?

NASDAQ:ME

ME Rankings

ME Latest News

ME Stock Data